Paradigm in the news

 
Paradigm Careers
08.03.17

TherapySelect announces they now exclusively offer the tumor biomarker profiling PCDx™ from Paradigm Diagnostics for an improved cancer therapy in Germany

Dieser Newsletter wird veröffentlicht von der / This newsletter is published by TherapySelect Dr. Frank Kischkel, Carl-Bosch-Str. 4, 69115 : To further improve cancer patient care we are pleased to inform you that we are now able to offer exclusively an efficacy test based on the analysis of molecular-based biomarker for targeted drugs (including anti-hormone-drugs […]

Read more
 
 
Paradigm Careers
05.03.17

Paradigm Diagnostics and TME Research Expand Precision Medicine Breast Cancer Registry

Phoenix, AZ and Allentown, PA, May 3, 2017– Paradigm Diagnostics and TME Research today announced an expanded national rollout of their Breast Cancer Registry. Paradigm’s Neoadjuvant Breast Registry or (NEAT), originally launched as a pilot in 2015, to utilize Paradigm’s Cancer Diagnostics Test (PCDx). The test characterizes the genomics of tumors from patients with invasive […]

Read more
 
 
Paradigm Careers
05.01.17

Paradigm Diagnostics Signs Contract With Arizona Medicaid Provider AHCCCS For Cancer Test

[Phoenix, AZ, May 1, 2017]—Paradigm Diagnostics, a molecular information & Next Generation Sequencing corporation specializing in providing cancer testing for patients with cancer, today announced that it has entered into a contractual agreement with AHCCCS for coverage of Paradigm Cancer Diagnostic (PCDxTM). Brian Wright, VP of Commercial Development and Marketing at Paradigm, noted, “Ensuring patients […]

Read more
 
 
Paradigm Careers
04.20.17

Paradigm Diagnostics Announces Recruiting of Clinical Trial Sites for Enrollment of New Personalized Medicine Cancer Registry

PHOENIX, April 20, 2017 /PRNewswire/ — Paradigm Diagnostics today announced the launch and IRB approval of the Paradigm registry to allow physicians to better collect, share, and visualize data to help advance personalized medicine in oncology. The Paradigm registry titled “A Prospective Registry Study to Evaluate the Efficacy of Precision Molecular Testing in the Treatment […]

Read more
 
 
Paradigm Careers
02.16.17

Paradigm Diagnostics Announces $7M Series B Financing

[Phoenix, AZ and New York, NY – February 16, 2017] – Paradigm Diagnostics today announced the near completion of their $7M Series B financing, adding an additional $3M from New Sciences Ventures on top of the $3.5M led by Mesa Verde Venture Partners and other strategic partners at the end of 2016. These resources will […]

Read more
 
 
Paradigm Careers
11.16.16

Paradigm Diagnostics Announces Initial Closing of $7M Series B Financing

Syndicate Includes Leading Venture and Strategic Investors; Proceeds to Support Research Collaborations and the Rapid Commercialization of the Paradigm Cancer Diagnostic Test – PCDx™ [Phoenix, AZ, November 16, 2016] — Paradigm Diagnostics today announced the first closing of a $7 million Series B financing to support the rapid commercial expansion of its PCDx tumor sequencing […]

Read more
 
 
Paradigm Careers
07.15.16

Independent Clinical Study Published Demonstrating Clinical Utility of the Paradigm Cancer Diagnostic (PCDx) Test

[PHOENIX, AZ, July 15, 2016]— An independent, peer-reviewed clinical study published today in Oncotarget entitled “Clinical Benefit of A Precision Medicine Based Approach For Guiding Treatment of Refractory Cancers” provides additional data supporting the clinical utility of the Paradigm PCDx test to significantly help improve outcomes for patients with cancer. This independent study was performed […]

Read more
 
 
Paradigm Careers
06.30.16

Paradigm and IDB Resources Announce Exclusive PCDx Tumor Profiling Service Agreement

Expands Global Distribution Of Cancer Testing Service to Southeast Asia [PHOENIX, AZ and PETALING JAYA, MALAYSIA, June 30, 2016]– Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing tumor analysis for patients with cancer to help find the optimal treatments, has signed a distribution agreement with IDB Resources to enable patient access […]

Read more
 
 
Paradigm Careers
05.18.16

Paradigm and CORE Diagnostics, India Announce Exclusive PCDx Tumor Profiling Service Agreement

[PHOENIX, AZ and NEW DELHI, INDIA, May 18, 2016]– Paradigm, a molecular information & Next Generation Sequencing (NGS) corporation specializing in providing tumor analysis for patients with cancer to help find the optimal treatments, has signed a distribution agreement with CORE Diagnostics to facilitate patient access to its cancer profiling service, PCDx, in India. Given […]

Read more
 
 
Paradigm Careers
11.09.15

Paradigm Leadership and TCGA Publish Study on Comprehensive Genomic Analysis of Primary Prostate Tumors in Cell

Paradigm Leadership played key leadership roles in a recently published study analyzing genomic changes in primary prostate tumors that has provided the most comprehensive and integrated view of gene changes for prostate cancer to date. In this National Institute of Health-funded, The Cancer Genome Atlas (TCGA) project, Paradigm leveraged experience and expertise from The International […]

Read more
 

Start getting better results, faster.

Order PCDx